Method for judging sensibility to imatinib

• US 20060246436A1
• Filed: 05/21/2003
• Published: 11/02/2006
• Est. Priority Date: 05/22/2002
• Status: Abandoned Application

• Current Assignee: University of Tokyo
• Original Assignee: University of Tokyo
• Inventors: Tsuruo, Takashi, Ohno, Ryuzo, Nakamura, Yusuke
• Application Number:
  US10/515,051
• Publication Number:
  US 20060246436A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

A method of judging whether a patient is sensitive to imatinib or not, in case where the patient is suffering from a disease such as CML to be treated by administration of imatinib, that is, a method for judging whether the administration of imatinib is effective for the therapy of the disease or not, is disclosed. Amounts of a plurality of genes selected from the group consisting of the specific 77 genes in sample cells separated from body are measured; and the measured amounts are compared with those of responders and non-responders to imatinib or a derivative thereof or a pharmaceutically acceptable salt thereof:

Claims

1. A method of judging sensitivity to imatinib or a derivative thereof or a pharmaceutically acceptable salt thereof, comprising measuring expression amounts of a plurality of genes selected from the group consisting of the following genes (1) to (77) in sample cells separated from body;

and comparing the measured amounts with those of responders and non-responders to imatinib or a derivative thereof or a pharmaceutically acceptable salt thereof;

(1)HN1(AI086871), (2)AKR1C3(D17793), (3)QARS(X76013), (4)KIAA1105(AA136180), (5)KIAA0668(AA506972), (6)BLCAP(AF053470), (7)ADFP(X97324), (8)FLJ10422(AA894857), (9)HMGCL(L07033), (10)EST(AI051454), (11)KLF4(AI290876), (12)H3F3A(M11354), (13)ACTB(V00478), (14)DKFZP566D193(AA401318), (15)APEX(U79268), (16)DRIL1(U88047), (17)BIN1(AF001383), (18)EST(AA495984), (19)CLTH(N41902), (20)M6PR(AA179832), (21 )KIAA0106(D14662), (22)IGF2R(J03528), (23)IDH1(AA330014), (24)EST(AI333449), (25)SDHB(AA365986), (26)TNRC3(AI743134), (27)MGP(AA156488), (28)CBLB(U26710), (29)EST(AA055355), (30)FLJ10803(T70782), (31)IMPDH1(J05272), (32)FLJ20489(AI091459), (33)GTF2I(U77948), (34)CGI-57(AF070638), (35)LOC51312(.AI128538), (36)CHAC(AA228874), (37)ATP1B1(X03747), (38)CPT1A(AA632225), (39)CTSG(M16117), (40)AXUD1(AI091372), (41)HLA-B(M28204), (42)GOLGA4(U31906), (43)EST(AA743462), (44)SCYA13(U46767), (45)B4GALT1(D29805), (46)DKFZP56400463(AA143048), (47)HSJ1(X63368), (48)MRPL3(X06323), (49)C9orf10(D80005), (50)DDX1(X70649), (51)EST(AA421326), (52)HLA-A(AF055066), (53)STIM1(AA101834), (54)AMPD2(M91029), (55)STX5A(U26648), (56)IFNB1(M25460), (57)MAEA(AI291745), (58)LBR(L25941), (59)LIMK2(D45906), (60)EST(AI365683), (61)RPL26(AA778161), (62)FLJ10209(AL137271), (63)FAAH(AA132519), (64)C21ORF33(Y07572), (65)EST(Z44513), (66)PRKACA(X07767), (67)EPB49(L19713), (68)EST(U51712), (69)CRSP9(AI334396), (70)EST(AA600323), (71)STK22B(L77564), (72)TRB@(X01410), (73)EEF1D(Z21507), (74)RPGR(U57629), (75)ARRB1(AA918725), (76)NOP5/NOP58(AA602490), (77)IGL@(M87790) (wherein the characters in parentheses after the symbol of each gene denote GenBank Accession No.)

2. The method according to claim 1, which is a method for judging sensitivity to imatinib or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 or 2, wherein the expression amounts of 10 to 35 genes among said genes are measured.

4. The method according to claim 3, wherein 10 to 35 genes from No. (1), in an ascending order, of said genes (1) to (35) are measured.

5. The method according to claim 4, wherein the expression amounts of said genes (1) to (15) or said genes (1) to (30) are measured.

6. The method according to any one of claims 1 to 5, wherein the step of comparing said measured expression amounts with those of the responders and non-responders comprises statistically calculating prediction score.

7. The method according to any one of claims 1 to 6, which is a method for predicting therapeutic effect of chronic myeloid leukemia by imatinib or a derivative thereof or a pharmaceutically acceptable salt thereof.

8. The method according to claim 7, wherein said sample cells are leukocyte cells.

9. The method according to claim 8, wherein said leukocyte cells are mononuclear cells.